

Rev04
Update: Oct,19,2022**DATASHEET**

Anti-Obinutuzumab Antibody, pAb, Rabbit

Cat. No.: A01933

Overview

Specificity	The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Host Species	Rabbit
Immunogen	Obinutuzumab
Conjugate	Unconjugated

Applications

Working concentrations for specific applications should be determined by the investigators. The appropriate concentration may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.


Application	Recommended Usage
ELISA	0.005-1 µg/ml

Properties

Form	Lyophilized
Storage Buffer	lyophilized with PBS, pH 7.4, contains 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
Storage Instructions	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Purification	Antigen affinity purification
Isotype	Rabbit IgG

Clonality	Polyclonal
Clone ID	Not applicable
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples



ELISA binding of Anti-Obinutuzumab Antibody, pAb, Rabbit (GenScript, A01933-40) with Obinutuzumab.
 Coating antigen: Obinutuzumab, 1 µg/ml.
 Anti-Obinutuzumab Antibody, pAb, Rabbit (GenScript, A01933-40) dilution start from 1,000 ng/ml, EC₅₀= 4.845 ng/ml.

Background

Target Background : Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naïve patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.

Synonyms : Rabbit polyclonal to Gazyva

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.